Blog
RSS FeedPosted by Michael Wonder on 10 Jun 2021
NICE recommends several treatment options to help thousands with moderate rheumatoid arthritis
10 June 2021 - Around 25,000 people with moderate rheumatoid arthritis that has not responded to conventional therapies are set to ...
Posted by Michael Wonder on 08 Jun 2021
NICE recommends Tecentriq for first-line NSCLC
7 June 2021 - NICE has recommended Roche’s Tecentriq (atezolizumab) monotherapy for untreated metastatic non-small cell lung cancer. ...
Posted by Michael Wonder on 06 Jun 2021
NICE publishes appraisal consultation document for medicine for excessive daytime sleepiness
3 June 2021 - The Department of Health and Social Care has asked the NICE to produce guidance on using pitolisant ...
Posted by Michael Wonder on 04 Jun 2021
NICE turns down GSK's IV Benlysta for systemic lupus
4 June 2021 - NICE has rejected NHS funding for an intravenous formulation of GlaxoSmithKline's Benlysta (belimumab) as an add-on ...
Posted by Michael Wonder on 02 Jun 2021
NICE ‘no’ to Roche’s risdiplam for SMA not unexpected, says patient group
2 June 2021 - NICE has rejected routine NHS funding for Roche’s Evrysdi (risdiplam) for spinal muscular atrophy drug in ...
Posted by Michael Wonder on 28 May 2021
NICE green lights Tremfya to treat active psoriatic arthritis
28 May 2021 - Janssen’s IL-23 inhibitor Tremfya has been accepted for NHS use by the UK’s NICE for the ...
Posted by Michael Wonder on 26 May 2021
NICE terminates yet another two appraisals
26 May 2021 - This is becoming far too commonplace. ...
Posted by Michael Wonder on 20 May 2021
NICE nod for BMS’ Opdivo in advanced oesophageal cancer
14 May 2021 - The UK NICE has recommended Bristol Myers Squibb’s Opdivo for the treatment of unresectable advanced oesophageal ...
Posted by Michael Wonder on 20 May 2021
NICE turns down Janssen's Erleada
20 May 2021 - NICE has published draft guidance rejecting Janssen's Erleada (apalutamide) with androgen deprivation therapy for treating prostate ...
Posted by Michael Wonder on 20 May 2021
Patients with rare blood disorders to receive new treatment option, says NICE
20 May 2021 - Hundreds of people with two rare blood disorders will soon have access to a new treatment regimen ...
Posted by Michael Wonder on 14 May 2021
NICE says final ‘no’ to BMS’ Zeposia for multiple sclerosis
14 May 2021 - NICE has issued a final “no” to Bristol-Myers Squibb’s oral MS drug Zeposia (ozanimod), in a ...
Posted by Michael Wonder on 14 May 2021
Colorectal cancer patients with rare mutations to benefit from life-extending treatment
14 May 2021 - NICE recommends pembrolizumab for colorectal cancer patients with rare mutations. ...
Posted by Michael Wonder on 12 May 2021
NICE rejects Pfizer’s rare heart disease treatment Vyndaqel
12 May 2021 - Pfizer’s Vyndaqel has been rejected by NICE as a treatment for the rare heart condition transthyretin ...
Posted by Michael Wonder on 07 May 2021
Avelumab not recommended as a maintenance treatment of urothelial cancer after platinum-based chemotherapy
7 May 2021 - NICE has issued draft guidance which does not recommend avelumab for maintenance treatment of locally advanced or ...
Posted by Michael Wonder on 28 Apr 2021
Thousands with high cholesterol set to benefit from new treatment on the NHS
28 April 2021 - Thousands of people with high cholesterol will soon have access to a new treatment option on the ...